Rafael E Jimenez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8305167/publications.pdf

Version: 2024-02-01

51 papers	1,266 citations	471371 17 h-index	377752 34 g-index
51 all docs	51 docs citations	51 times ranked	2153 citing authors

#	Article	IF	Citations
1	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-Î¤B Activation and PD-L1 Expression. Molecular Cell, 2019, 73, 22-35.e6.	4.5	174
2	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
3	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clinical Cancer Research, 2017, 23, 4704-4715.	3.2	117
4	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Molecular Cell, 2018, 71, 592-605.e4.	4.5	114
5	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer, 2020, 126, 26-36.	2.0	82
6	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	2.7	63
7	Surveillance after prostate focal therapy. World Journal of Urology, 2019, 37, 397-407.	1.2	63
8	Incidence of succinate dehydrogenase and fumarate hydrataseâ€“deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Human Pathology, 2019, 91, 114-122.	1.1	57
9	TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clinical Cancer Research, 2018, 24, 4551-4565.	3.2	51
10	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021, 12, 1521.	5.8	43
11	Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Human Pathology, 2021, 114, 9-18.	1.1	37
12	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open, 2016, 6, e010332.	0.8	32
13	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. Mayo Clinic Proceedings, 2021, 96, 1470-1489.	1.4	31
14	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS ONE, 2015, 10, e0145176.	1.1	26
15	Malakoplakia associated with prostatic adenocarcinoma. Annals of Diagnostic Pathology, 2016, 22, 33-37.	0.6	22
16	RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Theranostics, 2019, 9, 3459-3475.	4.6	22
17	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
18	Defining clear cell papillary renal cell carcinoma in routine clinical practice. Histopathology, 2020, 76, 1093-1095.	1.6	17

#	Article	IF	Citations
19	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Research, 2021, 9, 24.	5.4	17
20	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Annals of Surgical Oncology, 2018, 25, 3064-3068.	0.7	14
21	Frequency of diagnosis of cancer orÂhigh-risk lesion at operation forÂpathologic nipple discharge. Surgery, 2015, 158, 988-995.	1.0	13
22	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complexâ€“associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. European Urology, 2022, 81, 229-233.	0.9	12
23	Cellular fibroepithelial lesions of the breast: A long term follow up study. Annals of Diagnostic Pathology, 2018, 35, 85-91.	0.6	11
24	Secondary renal neoplasia following chemotherapy or radiation in pediatric patients. Human Pathology, 2020, 103, 1-13.	1.1	10
25	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery, 2021, 169, 644-648.	1.0	9
26	Morphologic overlap between low-grade oncocytic tumorÂand eosinophilic variant of chromophobe renal cell carcinoma. Human Pathology, 2022, 119, 114-116.	1.1	9
27	A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 14-22.	1.2	8
28	Renal neoplasia with papillary architecture involving the pelvicalyceal system. Human Pathology, 2021, 107, 46-57.	1.1	7
29	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
30	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 512-524.	0.8	6
31	MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma. Abdominal Radiology, 2021, 46, 5250-5259.	1.0	6
32	MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. Cancer Research, 2021, 81, 4471-4484.	0.4	5
33	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	2.8	4
34	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. Human Pathology, 2019, 88, 48-59.	1.1	2
35	Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468â€“77. European Urology, 2021, 80, e62-e63.	0.9	2
36	Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P).. Journal of Clinical Oncology, 2019, 37, e16559-e16559.	0.8	2

#	Article	IF	Citations
37	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. Human Pathology, 2022, 124, 85-95.	1.1	2
38	Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors. Mayo Clinic Proceedings, 2022, 97, 2050-2064.	1.4	2
39	The Tsarâ€™s doctor: The selfless and devoted life of Dr Eugene Botkin. Journal of Medical Biography, 2020, 29, 096777202093502.	0.1	1
40	Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.	2.0	1
41	Prostate MRI characteristics in patients with inflammatory bowel disease. European Journal of Radiology, 2021, 135, 109503.	1.2	1
42	Fumarate Hydratase (FH) c.1431_1433dupAAA (p.Lys477dup) variant is not associated with FH protein deficiency and increased 2SC in two separate patients with renal neoplasia. Human Mutation, 2021, 42, 1362-1364.	1.1	1
43	A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone.. Journal of Clinical Oncology, 2018, 36, 5038-5038.	0.8	1
44	Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5053-5053.	0.8	1
45	Abdominal Pain and Ileocolitis in a 51-Year-Old Woman. Gastroenterology, 2015, 148, e9-e10.	0.6	0
46	Predicting the biologic classification of phyllodes tumors from preoperative core needle biopsy and imaging findings.. Journal of Clinical Oncology, 2014, 32, 86-86.	0.8	0
47	Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 174-174.	0.8	0
48	Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 249-249.	0.8	0
49	A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 5056-5056.	0.8	0
50	Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).. Journal of Clinical Oncology, 2016, 34, 5036-5036.	0.8	0
51	â€œA monument to suffering and to patienceâ€: The harrowing journey of Nabby Adams through breast cancer. Journal of Medical Biography, 2022, , 096777202210977.	0.1	0